Has this billion-dollar fund made the right call on ARRY, VRX, and HIMX?
A glimpse into three biotech movers: ALDX, SAGE, AEMD.
Will TSLA, MU, BAC be catalysts for the recovery of this $14.4B fund?
Three key biopharma trades from the highly-successful $78 billion Renaissance fund
This hedge fund guru has made the right call on these three booming stocks.
Here are 5 reasons to buy Facebook stock.
These 3 pharmas are rising on positive clinical results data
Is Apple Inc. (NASDAQ:AAPL) looking overvalued right now? The $1 trillion mark is drawing increasingly …
Hedge Fund Guru Mark Kingdon Isn’t Taking Any Risks with OTIC, SGYP, ATRS
One of the World’s Most Powerful Fund Managers Displayed a Mixed Sentiment on Stock Giants